Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 2660 | 2107 | 40.6 | 88% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | BCL 2 | Author keyword | 85 | 11% | 36% | 759 |
| 2 | BCL 2 PROTEIN | Author keyword | 12 | 25% | 2% | 41 |
| 3 | BCL X | Author keyword | 11 | 22% | 2% | 46 |
| 4 | OBLIMERSEN | Author keyword | 7 | 46% | 1% | 11 |
| 5 | BCL 2 ONCOPROTEIN | Author keyword | 5 | 45% | 0% | 9 |
| 6 | BCL 2 EXPRESSION | Author keyword | 5 | 31% | 1% | 13 |
| 7 | ANTISENSE BCL 2 | Author keyword | 4 | 75% | 0% | 3 |
| 8 | BCL 2 PROTOONCOGENE | Author keyword | 3 | 60% | 0% | 3 |
| 9 | BCL 2 ONCOGENE | Author keyword | 2 | 38% | 0% | 5 |
| 10 | G3139 | Author keyword | 2 | 29% | 0% | 7 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | BCL 2 | 85 | 11% | 36% | 759 | Search BCL+2 | Search BCL+2 |
| 2 | BCL 2 PROTEIN | 12 | 25% | 2% | 41 | Search BCL+2+PROTEIN | Search BCL+2+PROTEIN |
| 3 | BCL X | 11 | 22% | 2% | 46 | Search BCL+X | Search BCL+X |
| 4 | OBLIMERSEN | 7 | 46% | 1% | 11 | Search OBLIMERSEN | Search OBLIMERSEN |
| 5 | BCL 2 ONCOPROTEIN | 5 | 45% | 0% | 9 | Search BCL+2+ONCOPROTEIN | Search BCL+2+ONCOPROTEIN |
| 6 | BCL 2 EXPRESSION | 5 | 31% | 1% | 13 | Search BCL+2+EXPRESSION | Search BCL+2+EXPRESSION |
| 7 | ANTISENSE BCL 2 | 4 | 75% | 0% | 3 | Search ANTISENSE+BCL+2 | Search ANTISENSE+BCL+2 |
| 8 | BCL 2 PROTOONCOGENE | 3 | 60% | 0% | 3 | Search BCL+2+PROTOONCOGENE | Search BCL+2+PROTOONCOGENE |
| 9 | BCL 2 ONCOGENE | 2 | 38% | 0% | 5 | Search BCL+2+ONCOGENE | Search BCL+2+ONCOGENE |
| 10 | G3139 | 2 | 29% | 0% | 7 | Search G3139 | Search G3139 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | HUMAN FOLLICULAR LYMPHOMA | 51 | 42% | 4% | 92 |
| 2 | CHROMOSOMAL BREAKPOINT | 22 | 28% | 3% | 66 |
| 3 | PROTOONCOGENE BCL 2 | 12 | 23% | 2% | 47 |
| 4 | 938C GREATER THAN A | 10 | 73% | 0% | 8 |
| 5 | CHEMOTHERAPY INDUCED APOPTOSIS | 9 | 15% | 3% | 54 |
| 6 | DEREGULATED BCL2 | 8 | 75% | 0% | 6 |
| 7 | BCL 2 PROTEIN | 7 | 11% | 3% | 56 |
| 8 | REGULATORY P53 | 6 | 100% | 0% | 4 |
| 9 | SUPPRESSING PROTEIN BCL 2 | 5 | 63% | 0% | 5 |
| 10 | HOMOLOG BAK | 5 | 25% | 1% | 16 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Molecular thanatopsis: A discourse on the BCL2 family and cell death | 1996 | 1130 | 140 | 48% |
| BCL2 family in DNA damage and cell cycle control | 2006 | 235 | 79 | 41% |
| BCL-2 AND THE REGULATION OF PROGRAMMED CELL-DEATH | 1994 | 2009 | 59 | 64% |
| The role of Bcl-2 family members in tumorigenesis | 2004 | 276 | 231 | 34% |
| Oblimersen bcl-2 antisense: Facilitating apoptosis in anticancer treatment | 2002 | 171 | 86 | 48% |
| The proto-oncogene Bcl-2 and its role in regulating apoptosis | 1997 | 1405 | 62 | 18% |
| Targeting the Bcl-2 | 2009 | 37 | 67 | 52% |
| Targeting Bcl-2 and Bcl-X-L with nonpeptidic small-molecule antagonists | 2003 | 89 | 57 | 49% |
| Loss of Bcl-2 expression in colon cancer: A prognostic factor for recurrence in stage II colon cancer | 2009 | 22 | 25 | 68% |
| Bcl-2 antisense oligonucleotides: A potential novel strategy for the treatment of breast cancer | 2003 | 45 | 52 | 75% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | ONCOGENE TUMOR SUPP SOR GENE PROGRAM | 2 | 44% | 0.2% | 4 |
| 2 | AREA BIOPATOL | 1 | 100% | 0.1% | 2 |
| 3 | AZIENDA OSPEDALIERA MONALDI | 1 | 100% | 0.1% | 2 |
| 4 | EXPT ONCOL MOL PHARMACOL | 1 | 100% | 0.1% | 2 |
| 5 | SHAHEED RAJGURU PL SCI | 1 | 50% | 0.1% | 2 |
| 6 | ROY J LUCILLE P CARVER MED | 1 | 33% | 0.1% | 3 |
| 7 | ODONTOL ORAL PATHOL FORENS ODONTOL | 1 | 19% | 0.2% | 5 |
| 8 | HOSP DURAN REYNALS | 1 | 10% | 0.4% | 9 |
| 9 | ALBERT E EIN MONTEFIORE CANC | 1 | 27% | 0.1% | 3 |
| 10 | AFFILIATED SHAANXI PROV CANC HOSP | 1 | 50% | 0.0% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000235611 | BCL2L12//BCL2 FAMILY//G P ANICOLAOU ONCOL |
| 2 | 0.0000172343 | BIKDD//MITOCHONDRIAL CYTOCHROME C RELEASE//BAX OVEREXPRESSION |
| 3 | 0.0000145749 | MGDC//VERRUCARIN A//RADIAT TUMOR PHYSIOL |
| 4 | 0.0000141549 | MCL 1//ABT 737//BCL 2 FAMILY |
| 5 | 0.0000126959 | HIGH MOLECULAR WEIGHT DNA FRAGMENTATION//CA2 MG2 DEPENDENT ENDONUCLEASE//APO27 |
| 6 | 0.0000117115 | FOLLICULAR LYMPHOMA//T1418//IN SITU FOLLICULAR LYMPHOMA |
| 7 | 0.0000090239 | TAT BH4//MOL CELLULAR SIGNALING//BIOEMERGENCES IBISA |
| 8 | 0.0000080732 | GROWTH FACTOR DEPRIVATION THERAPY//A63162//MED DISCOVERY |
| 9 | 0.0000078404 | HEMATOL ONCOLWINSHIP CANC//MICROTUBULE ACTIVE DRUGS//PHARMACOLRAMMELKAMP EDUC |
| 10 | 0.0000070229 | APAF 1//CASPASE 2//RAIDD |